Comparative Pharmacology
Head-to-head clinical analysis: MIUDELLA versus ORTHO NOVUM 7 14 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIUDELLA versus ORTHO NOVUM 7 14 21.
MIUDELLA vs ORTHO-NOVUM 7/14-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Category C
Category C
Oral Contraceptive
Oral Contraceptive